Appointment dossier — Uterine Carcinosarcoma
Bring this to your appointment. It summarizes what published studies report — it is not medical advice and does not say anything works. Decisions are yours and your care team’s.
Compounds studied in Uterine Carcinosarcoma
- Carboplatin — Human evidence · 2 positive / 1 negative-mixed · PMID 38154864, 35007153, 33183764
- Paclitaxel — Human evidence · 2 positive · PMID 38154864, 35007153
- Trastuzumab Deruxtecan — Human evidence · 2 positive · PMID 39639215, 36977309
- Ifosfamide — Human evidence · 1 positive · PMID 35007153
- Trastuzumab-Deruxtecan (T-Dxd) — Human evidence · 1 positive · PMID 39639215
- Tamoxifen — Human evidence · 0 positive · PMID 11578496
- Sacituzumab Govitecan — Animal evidence · 1 positive · PMID 40344963
“Positive” means a study reported a positive result — most are early lab/animal work that may not translate to people.
Open recruiting trials (18)
- NCT05902988 · Phase 1 / Phase 2 — A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer (United States)
- NCT05269381 · Phase 1 / Phase 2 — Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors (United States)
- NCT03686124 · Phase 1 / Phase 2 — ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors (United States)
- NCT07612891 · Phase 1 / Phase 2 — A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of INV-6452 in Adult Patients With Hormone Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Advanced/Metastatic Breast Cancer or Locally Advanced/Metastatic Solid Tumor (China)
- NCT06535607 · Phase 2 — Study of Volrustomig as Monotherapy or in Combination With Anti- Cancer Agents in Participants With Advanced/Metastatic Solid Tumors (United States)
- NCT06215950 · Phase 1 — A Clinical Research About CD70-targeted CAR-T in the Treatment of CD70-positive Advanced/Metastatic Gynecologic Cancer (China)
- NCT05856981 · Phase 1 — Phase 1 Study Evaluating the Safety and PK of ADU-1805 in Advanced Solid Tumors (United States)
- NCT06349642 — Immune Checkpoint Inhibitor Response in Solid Tumors Using a Live Tumor Diagnostic Platform (United States)
- NCT07782164 — Irreversible Electroporation (IRE) for Treating Recurrent Pelvic Tumors (PELFIRE Study) (Netherlands)
- NCT05256225 · Phase 3 — Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma (United States)
- NCT03422198 · Phase 3 — Short Course Vaginal Cuff Brachytherapy in Treating Participants With Stage I-II Endometrial Cancer (United States)
- NCT05646316 · Phase 3 — Impact of Sentinel Lymph Node Mapping on Patient Reported Lower Extremity Limb Dysfunction in Stage I Endometrial Cancer (United States)
- NCT05559879 · Phase 1 / Phase 2 — Cabozantinib and Dostarlimab in Recurrent Gynecologic Carcinosarcoma (United States)
- NCT04098744 · Phase 2 — Artesunate Vaginal Inserts for the Treatment of Cervical Intraepithelial Neoplasia (CIN2/3) (United States)
- NCT07454915 · Phase 2 — PVX4 for the Treatment of Human Papilloma Virus (HPV)16+ Cervical Dysplasia (United States)
- NCT06630611 · Phase 2 — Evaluation of a Pragmatic Approach to Adoptive Cell Therapy (ACT) Using an IL2 Analog (ANV419) vs High Dose IL2 After Tumor Infiltrating Lymphocytes (TIL) Therapy in Patients With Melanoma, NSCLC and Cervical Cancer (PragmaTIL) (Spain)
- NCT05542407 · Phase 1 — ONC201 and Atezolizumab in Obesity-Driven Endometrial Cancer (United States)
- NCT05483491 · Phase 1 — KK-LC-1 TCR-T Cell Therapy for Gastric, Breast, Cervical, and Lung Cancer (United States)
Most-relevant first: trials that name Uterine Carcinosarcoma, then broader trials you may still qualify for. Eligibility is decided by each trial's team — bring these NCT numbers to your appointment.
Financial help to look into
- PAN Foundation — Copay assistance funds by diagnosis (funds open and close as money allows). https://www.panfoundation.org/
- HealthWell Foundation — Copay and premium assistance funds by disease. https://www.healthwellfoundation.org/
- CancerCare — financial assistance — Limited grants plus free financial counseling. https://www.cancercare.org/financial
- Family Reach — Help with everyday living costs (rent, transport, food) during treatment. https://familyreach.org/
- NeedyMeds — Searchable directory of drug patient-assistance and discount programs. https://www.needymeds.org/
For each medicine above, search manufacturer and nonprofit programs at medicineassistancetool.org.
Questions to ask your oncologist
- I've read that Carboplatin has been studied in people for Uterine Carcinosarcoma — what's the evidence, and is it an option or available in a trial for me?
- I've read that Paclitaxel has been studied in people for Uterine Carcinosarcoma — what's the evidence, and is it an option or available in a trial for me?
- I've read that Trastuzumab Deruxtecan has been studied in people for Uterine Carcinosarcoma — what's the evidence, and is it an option or available in a trial for me?
- Of the open trials I found (for example NCT05902988), am I eligible for any — here or at a larger cancer center?
- What is my exact diagnosis — the type, subtype, stage, and grade?
- Has my tumor had molecular or genomic testing (e.g. next-generation sequencing), and what did it find?
- Should I have inherited (germline) genetic testing, and could it affect my treatment or my family?
- What is the goal of treatment for me — cure, long-term control, or comfort?
- What are all of my standard treatment options, and what does each one involve?
- What is the realistic benefit of each option, in actual numbers?
- What are the most common and the most serious side effects, and how are they managed?
- How will we know if treatment is working, and how often will I be scanned or tested?
- If the first treatment doesn't work, what are the next options?
- Are there gentler options if I want to prioritize quality of life?
- Am I eligible for any clinical trials — here or at a larger/academic cancer center?
- Is my case reviewed by a multidisciplinary tumor board?
- Would a second opinion at a center that treats my cancer often be worthwhile?
- Could any of my prescriptions, over-the-counter drugs, or supplements interfere with treatment?
- Which symptoms are emergencies, and who do I call after hours?
- Should I see palliative or supportive care alongside my treatment?
- How will treatment affect my daily life, work, and (if it matters to me) fertility?
- What can I safely do myself — diet and activity — and is anything I'm taking risky?